Literature DB >> 31845175

Tanshinone IIA Ameliorates CNS Autoimmunity by Promoting the Differentiation of Regulatory T Cells.

Ye Gong1, Yuan-Chu Liu1, Xiao-Li Ding1, Ying Fu1, Lang-Jun Cui2,3, Ya-Ping Yan4,5.   

Abstract

Tanshinone IIA (TSA), an important natural lipophilic diterpene compound from the traditional Chinese herb Salvia miltiorrhiza Bunge, has long been widely used for the prevention and treatment of various diseases because of its anti-inflammatory activities; however, the anti-inflammatory mechanism remains unknown. In the present work, we examined the effects of TSA on experimental autoimmune encephalomyelitis (EAE), a model of autoreactive T/B cell-mediated central nervous system (CNS) autoimmunity. The data showed that TSA significantly attenuates the severity of EAE when administered at the pre-onset and peak of clinical disease. In vivo, the protective effects of TSA on EAE mice are correlated with diminished inflammatory infiltration, demyelination, and GM-CSF-producing CD4+ T cells in the spinal cord and selectively increased regulatory T (Treg) cell frequencies in both the spinal cord and spleen. We further confirm that TSA can promote the polarization of naïve CD4+ T cells into Treg cells both by targeting dendritic cells (DCs) to drive transforming growth factor β1 (TGF-β1) upregulation and by directly targeting naïve CD4+ T cells in vitro. Most importantly, we showed that TSA-induced Treg cells display an effective suppressive activity at a level comparable to TGF-β1-polarized Treg Cells in vitro and in vivo. Taken together, our data provide evidence that TSA can promote Treg cell differentiation, and TSA may have a promising application as a therapeutic agent for the treatment of neuroinflammatory diseases.

Entities:  

Keywords:  Tanshinone IIA (TSA); Treg cell; experimental autoimmune encephalomyelitis (EAE); multiple sclerosis (MS); transforming growth factor β1 (TGF-β1)

Mesh:

Substances:

Year:  2020        PMID: 31845175      PMCID: PMC7283442          DOI: 10.1007/s13311-019-00789-2

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  49 in total

Review 1.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

Review 3.  Models of multiple sclerosis: new insights into pathophysiology and repair.

Authors:  Hans Lassmann
Journal:  Curr Opin Neurol       Date:  2008-06       Impact factor: 5.710

Review 4.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 5.  Regulatory T cells in autoimmune neuroinflammation.

Authors:  Markus Kleinewietfeld; David A Hafler
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

Review 6.  Mechanisms underlying inflammation in neurodegeneration.

Authors:  Christopher K Glass; Kaoru Saijo; Beate Winner; Maria Carolina Marchetto; Fred H Gage
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 7.  Multiple sclerosis.

Authors:  Elliot M Frohman
Journal:  Med Clin North Am       Date:  2003-07       Impact factor: 5.456

8.  Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells.

Authors:  Ying Lu; Bing Chen; Jun-Hong Song; Tao Zhen; Bai-Yan Wang; Xin Li; Ping Liu; Xin Yang; Qun-Ling Zhang; Xiao-Dong Xi; Sheng-Di Chen; Jian-Ping Zuo; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-23       Impact factor: 11.205

9.  Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes.

Authors:  Anneli Jäger; Valérie Dardalhon; Raymond A Sobel; Estelle Bettelli; Vijay K Kuchroo
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

10.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

View more
  3 in total

1.  Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo.

Authors:  Peipei Luo; Yanqiang Huang; Xudong Hang; Qian Tong; Liping Zeng; Jia Jia; Guoxin Zhang; Hongkai Bi
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 2.  Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis.

Authors:  Ruoyu Li; Hui Li; Xiaoyan Yang; Huiru Hu; Peidong Liu; Hongbo Liu
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

Review 3.  Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases.

Authors:  Rui Guo; Lan Li; Jing Su; Sheng Li; Sophia Esi Duncan; Zhihao Liu; Guanwei Fan
Journal:  Drug Des Devel Ther       Date:  2020-11-05       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.